Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Citi initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $70 price target Healthcare policy remains a key biopharma sector ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform ...

BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to muscle and heart cells. Learn more on RNA stock here.

Analysts have recently evaluated Avidity Biosciences and provided 12-month price targets. The average target is $69.0, ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price gapped down before the market opened on Monday after Barclays lowered their price target on the stock from $63.00 to $57.00. The ...

In March, Avidity reported positive del-desiran long-term 4 mg/kg data from the MARINA-OLE™ study showing reversal of disease ...

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago.

SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...